We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Hematopoietic stem cell (HSC) can be either allogeneic (from another person) or autologous (from the recipient). Autologous hematopoietic stem cell transplantation (HSCT) was first suggested by Burt as a form of intense immunesuppressive therapy. HSCT was proposed as a treatment for multiple sclerosis (MS) based on favorable results in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The toxicity and efficacy of an autologous HSCT is entirely a consequence of the conditioning regimen. Initial HSCT protocols employed aggressive malignancy-specific myeloablative regimens in patients with progressive MS. Unlike autologous HSCT, the immune compartment arising from allogeneic stem cells have a different and presumably more disease-resistant genetic predisposition towards disease recurrence. Both autologous and allogeneic HSCT require a chemotherapy conditioning regimen to suppress or ablate the immune system. HSCT is the only therapy to consistently demonstrate improvement in neurological disability.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.